Loading...
•
Mar 31, 2021
Amphastar Q1 2021 Earnings Report
Reported net revenues of $103.0 million and GAAP net income of $5.0 million for the first quarter.
Key Takeaways
Amphastar Pharmaceuticals reported a strong first quarter with net revenues of $103.0 million, driven by the launch of glucagon and increased sales of Primatene Mist and epinephrine products. GAAP net income was $5.0 million, or $0.10 per share, and adjusted non-GAAP net income was $13.6 million, or $0.27 per share.
Net revenues reached $103.0 million.
GAAP net income was $5.0 million, or $0.10 per share.
Adjusted non-GAAP net income was $13.6 million, or $0.27 per share.
The launch of glucagon and strong sales of Primatene Mist and epinephrine products drove growth.
Revenue by Segment
Forward Guidance
The company expects core growth products will continue to drive growth for the remainder of the year and is confident in seeing their pipeline develop to diversify their portfolio.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...